Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne Clinical Trial

— NORTH POLE DMD  

Official title:

Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01918384
• Other study ID #: NPC-14-1
• Secondary ID: JMA-IIA00134
• Status: Active, not recruiting
• Phase: Phase 2
• First received: August 1, 2013
• Last updated: September 2, 2015
• Start date: August 2013
• Est. completion date: October 2015

Study information

• Verified date: September 2015
• Source: Kobe University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and WelfareJapan: Pharmaceuticals and Medical Devices Agency
• Study type: Interventional

Clinical Trial Summary

Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 4 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of DMD resulting from a nonsense mutation by whole genome sequencing of the dystrophin gene

2. To have intact right or left biceps muscles, or an alternative muscle group that is able to be underwent for appropriate evaluation of efficacy

3. To meet the following criteria at screening (baseline visit), within 30 days prior to the first dose of study drug

• Ambulant and able to walk at least 75 meters during the 6MWT

• Able to comply with and complete all protocol requirements, and judged by the investigator to be appropriate to participate in the study from the screening results

4. Aged at least 4 years at the time of giving informed consent

5. Male

6. Able to be hospitalized for the study requirement

7. Signed Informed consent by parents/legal guardian and/or signed assent by the subject (age of assent to be determined by IRB)

Exclusion Criteria:

1. Prior exposure to investigational medicines that have a potential of restoring dystrophin or other functional protein (readthrough, exon skipping, utrophin upregulation therapy etc.)

2. Known mutation at nucleotide 1555 in 12S rRNA gene of mitochondrial DNA, and/or personally or families have been treated or have a history of eight cranial nerve disorder (hearing loss?vertigo?tinnitus etc.)as a result of aminoglycoside use

3. Inability to hear within the range of 0 to 25 dB by pure tone audiometry, abnormalities on auditory brainstem response audiometry, and/or loss of frequency by distortion product oto acoustic emissions at screening

4. Poor oral intake or enable to oral intake, and/or bad general status

5. Known allergies to NPC-14, other aminoglycosides, and/or bacitracin

6. Presence of anti-dystrophin antibody at the baseline assessments

7. Cys-C =1.2 mg/L and/or creatinine concentration >1.5 times the upper limit of age corrected normal range

8. Left ventricular ejection fraction (EF) <40% or left ventricular fractional shortening (FS) <25%, and/or =480 msec QTc (corrected QT interval by Fridericia's method)

9. Need of mechanical ventilation

10. Forced vital capacity (FVC) <50% predicted

11. Clinically significant concomitant diseases (hematology, psychoneurotic, hepatic, pulmonary, endocrine, immune, renal, and gastroenterological diseases), and/or cancer

12. Impairment of intellectual functions, and/or expressive language ability which might interfere with study assessments

13. Treatment with other systemic aminoglycoside within 6 months prior to the first administration of study drug

14. Initiation of systemic glucocorticosteroids treatment, and/or start exercise cure, physical therapy, or occupational therapy which might interfere with study assessments. Changing of dose and schedule of systemic glucocorticosteroids within 6 months prior to the first administration of study drug

15. History of any surgical procedure within months prior to the first administration of study drug or have a plan during study

16. History of sever allergy from food and medicine like an anaphylaxis shock or generalized rash

17. Participation in any other clinical trial and intake of any investigational drug within 6month of study entry

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Drug:
• NPC-14
NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist. An initial dose of NPC-14 will be half of that calculated by distribution volume:Vd based on patient age for safety reason. After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14
• Placebo
Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen

Locations

Country	Name	City	State
Japan	Kobe university hospital, department of pediatrics	Kobe	Hyogo prefecture
Japan	National center of neurology and psychiatry	Kodaira	Tokyo
Japan	Hyogo College of Medicine	Nishinomiya	Hyogo prefecture
Japan	Tokyo Women's Medical University	Shinjuku-ku	Tokyo

Sponsors (3)

Lead Sponsor	Collaborator
Kobe University	Japan Medical Association, Nobelpharma

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability (Adverse events)		Up to 38 weeks (36 weeks treatment period and 2 weeks follow up period)	Yes
Primary	Change of dystrophin expression rate in muscle tissues from the baseline assessment		At 37 weeks (1 week after from 36 weeks treatment period)	No
Secondary	North Star Ambulatory Assessment		At 36 weeks	No
Secondary	Timed test (6MWT, time to walk/run 10 meters, time to climb/descent four steps, time to rise from the floor)		At 36 weeks	No
Secondary	Muscle strength (MMT, QMT)		At 36 weeks	No
Secondary	Dairy activities		At 36 weeks	No
Secondary	Biomarkers (CK, ALD)		At 36 weeks	No